# Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

*PRI Rank #5 · Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026/rank-5*

| Field | Value |
| --- | --- |
| Rank | #5 |
| 18m citations | 60 |
| Journal | Blood |
| Year | 2024 |
| DOI | 10.1182/blood.2024025454 |
| Corresponding authors | Laurie H Sehn |
| Institution | BC Cancer Centre for Lymphoid Cancer, Canada |

**Ranking page:** [Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026](https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026)

**Paper link:** [10.1182/blood.2024025454](https://doi.org/10.1182/blood.2024025454)

## Topics

Mosunetuzumab · CD20-targeted therapy · T-cell-engaging bispecific antibody · Relapsed/refractory follicular lymphoma · Fixed-duration treatment · Complete response rate · Objective response rate · Duration of response · Progression-free survival · Overall survival · CD19+ B-cell recovery · cytokine release syndrome · Off-the-shelf therapy · Outpatient administration · High-risk disease · Phase I/II trial · NCT02500407 · Long-term follow-up safety · T-cell-engaging bispecific antibody · ≥2 prior lines of therapy

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026. Accessed 2026-07-15.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```